1.Changing Trends What Patients with Thyroid Cancer Surgery Are Concerned About: Comparison between 2012 and 2020
Minjin LEE ; Hyeok Jun YUN ; Kyung Ah PARK ; Jihye HEO ; Hanna KIM ; Yong Sang LEE ; Hang-Seok CHANG ; Cheong Soo PARK
International Journal of Thyroidology 2022;15(1):28-35
Background and Objectives:
Given the major changes in spread of COVID-19 and the contribution of technological innovation, the objective of the current study was to compare the educational needs of thyroid cancer patients between 2012 and 2020.
Materials and Methods:
The subject of this study were 159 patients in 2012 and 149 patients in 2020 who underwent thyroid cancer surgery. Data were collected from September 2020 to December 2020. Their responses were compared with response for the 2012 survey. The survey contained 36 questions regarding demographics and 5 areas of educational needs (Treatment plan after discharge, Management of the symptom and the complication after surgery, Medication management, Postoperative wound and dietary management, Daily life).
Results:
The most preferred teaching method for thyroid cancer surgery patients has changed from small group education to self-study with videos. The Internet accounted for the largest proportion of source of information and the preferred educator for the patient were doctors and nurses in both 2012 and 2020. ‘Current disease condition and surgical result’ was the highest ranked in both 2012 and 2020.
Conclusion
It is necessary to develop and utilize an educational method using video centered on medical team including doctors and nurses.
2.Technical Feasibility of Quantitative Measurement of Various Degrees of Small Bowel Motility Using Cine Magnetic Resonance Imaging
Ji Young CHOI ; Jihye YUN ; Subin HEO ; Dong Wook KIM ; Sang Hyun CHOI ; Jiyoung YOON ; Kyuwon KIM ; Kee Wook JUNG ; Seung-Jae MYUNG
Korean Journal of Radiology 2023;24(11):1093-1101
Objective:
Cine magnetic resonance imaging (MRI) has emerged as a noninvasive method to quantitatively assess bowel motility. However, its accuracy in measuring various degrees of small bowel motility has not been extensively evaluated. We aimed to draw a quantitative small bowel motility score from cine MRI and evaluate its performance in a population with varying degrees of small bowel motility.
Materials and Methods:
A total of 174 participants (28.5 ± 7.6 years; 135 males) underwent a 22-second-long cine MRI sequence (2-dimensional balanced turbo-field echo; 0.5 seconds per image) approximately 5 minutes after being intravenously administered 10 mg of scopolamine-N-butyl bromide to deliberately create diverse degrees of small bowel motility. In a manually segmented area of the small bowel, motility was automatically quantified using a nonrigid registration and calculated as a quantitative motility score. The mean value (MV) of motility grades visually assessed by two radiologists was used as a reference standard. The quantitative motility score’s correlation (Spearman’s ρ) with the reference standard and performance (area under the receiver operating characteristics curve [AUROC], sensitivity, and specificity) for diagnosing adynamic small bowel (MV of 1) were evaluated.
Results:
For the MV of the quantitative motility scores at grades 1, 1.5, 2, 2.5, and 3, the mean ± standard deviation values were 0.019 ± 0.003, 0.027 ± 0.010, 0.033 ± 0.008, 0.032 ± 0.009, and 0.043 ± 0.013, respectively. There was a significant positive correlation between the quantitative motility score and the MV (ρ = 0.531, P < 0.001). The AUROC value for diagnosing a MV of 1 (i.e., adynamic small bowel) was 0.953 (95% confidence interval, 0.923–0.984). Moreover, the optimal cutoff for the quantitative motility score was 0.024, with a sensitivity of 100% (15/15) and specificity of 89.9% (143/159).
Conclusion
The quantitative motility score calculated from a cine MRI enables diagnosis of an adynamic small bowel, and potentially discerns various degrees of bowel motility.
3.Difference in Baseline Antimicrobial Prescription Patterns of Hospitals According to Participation in the National Antimicrobial Monitoring and Feedback System in Korea
Jihye SHIN ; Ji Young PARK ; Jungmi CHAE ; Hyung-Sook KIM ; Song Mi MOON ; Eunjeong HEO ; Se Yoon PARK ; Dong Min SEO ; Ha-Jin CHUN ; Yong Chan KIM ; Myung Jin LEE ; Kyungmin HUH ; Hyo Jung PARK ; I Ji YUN ; Su Jin JEONG ; Jun Yong CHOI ; Dong-Sook KIM ; Bongyoung KIM ;
Journal of Korean Medical Science 2024;39(29):e216-
This study aimed to evaluate the differences in the baseline characteristics and patterns of antibiotic usage among hospitals based on their participation in the Korea National Antimicrobial Use Analysis System (KONAS). We obtained claims data from the National Health Insurance for inpatients admitted to all secondary- and tertiary-care hospitals between January 2020 and December 2021 in Korea. 15.9% (58/395) of hospitals were KONAS participants, among which the proportion of hospitals with > 900 beds (31.0% vs.2.6%, P < 0.001) and tertiary care (50.0% vs. 5.2%, P < 0.001) was higher than that among non-participants. The consumption of antibiotics targeting antimicrobial-resistant gram positive bacteria (33.7 vs. 27.1 days of therapy [DOT]/1,000 patient-days, P = 0.019) and antibiotics predominantly used for resistant gram-negative bacteria (4.8 vs. 3.7 DOT/1,000 patient-days, P = 0.034) was higher in KONAS-participating versus -non-participating hospitals. The current KONAS data do not fully represent all secondary- and tertiary-care hospitals in Korea; thus, the KONAS results should be interpreted with caution.
4.Difference in Baseline Antimicrobial Prescription Patterns of Hospitals According to Participation in the National Antimicrobial Monitoring and Feedback System in Korea
Jihye SHIN ; Ji Young PARK ; Jungmi CHAE ; Hyung-Sook KIM ; Song Mi MOON ; Eunjeong HEO ; Se Yoon PARK ; Dong Min SEO ; Ha-Jin CHUN ; Yong Chan KIM ; Myung Jin LEE ; Kyungmin HUH ; Hyo Jung PARK ; I Ji YUN ; Su Jin JEONG ; Jun Yong CHOI ; Dong-Sook KIM ; Bongyoung KIM ;
Journal of Korean Medical Science 2024;39(29):e216-
This study aimed to evaluate the differences in the baseline characteristics and patterns of antibiotic usage among hospitals based on their participation in the Korea National Antimicrobial Use Analysis System (KONAS). We obtained claims data from the National Health Insurance for inpatients admitted to all secondary- and tertiary-care hospitals between January 2020 and December 2021 in Korea. 15.9% (58/395) of hospitals were KONAS participants, among which the proportion of hospitals with > 900 beds (31.0% vs.2.6%, P < 0.001) and tertiary care (50.0% vs. 5.2%, P < 0.001) was higher than that among non-participants. The consumption of antibiotics targeting antimicrobial-resistant gram positive bacteria (33.7 vs. 27.1 days of therapy [DOT]/1,000 patient-days, P = 0.019) and antibiotics predominantly used for resistant gram-negative bacteria (4.8 vs. 3.7 DOT/1,000 patient-days, P = 0.034) was higher in KONAS-participating versus -non-participating hospitals. The current KONAS data do not fully represent all secondary- and tertiary-care hospitals in Korea; thus, the KONAS results should be interpreted with caution.
5.Difference in Baseline Antimicrobial Prescription Patterns of Hospitals According to Participation in the National Antimicrobial Monitoring and Feedback System in Korea
Jihye SHIN ; Ji Young PARK ; Jungmi CHAE ; Hyung-Sook KIM ; Song Mi MOON ; Eunjeong HEO ; Se Yoon PARK ; Dong Min SEO ; Ha-Jin CHUN ; Yong Chan KIM ; Myung Jin LEE ; Kyungmin HUH ; Hyo Jung PARK ; I Ji YUN ; Su Jin JEONG ; Jun Yong CHOI ; Dong-Sook KIM ; Bongyoung KIM ;
Journal of Korean Medical Science 2024;39(29):e216-
This study aimed to evaluate the differences in the baseline characteristics and patterns of antibiotic usage among hospitals based on their participation in the Korea National Antimicrobial Use Analysis System (KONAS). We obtained claims data from the National Health Insurance for inpatients admitted to all secondary- and tertiary-care hospitals between January 2020 and December 2021 in Korea. 15.9% (58/395) of hospitals were KONAS participants, among which the proportion of hospitals with > 900 beds (31.0% vs.2.6%, P < 0.001) and tertiary care (50.0% vs. 5.2%, P < 0.001) was higher than that among non-participants. The consumption of antibiotics targeting antimicrobial-resistant gram positive bacteria (33.7 vs. 27.1 days of therapy [DOT]/1,000 patient-days, P = 0.019) and antibiotics predominantly used for resistant gram-negative bacteria (4.8 vs. 3.7 DOT/1,000 patient-days, P = 0.034) was higher in KONAS-participating versus -non-participating hospitals. The current KONAS data do not fully represent all secondary- and tertiary-care hospitals in Korea; thus, the KONAS results should be interpreted with caution.
6.Difference in Baseline Antimicrobial Prescription Patterns of Hospitals According to Participation in the National Antimicrobial Monitoring and Feedback System in Korea
Jihye SHIN ; Ji Young PARK ; Jungmi CHAE ; Hyung-Sook KIM ; Song Mi MOON ; Eunjeong HEO ; Se Yoon PARK ; Dong Min SEO ; Ha-Jin CHUN ; Yong Chan KIM ; Myung Jin LEE ; Kyungmin HUH ; Hyo Jung PARK ; I Ji YUN ; Su Jin JEONG ; Jun Yong CHOI ; Dong-Sook KIM ; Bongyoung KIM ;
Journal of Korean Medical Science 2024;39(29):e216-
This study aimed to evaluate the differences in the baseline characteristics and patterns of antibiotic usage among hospitals based on their participation in the Korea National Antimicrobial Use Analysis System (KONAS). We obtained claims data from the National Health Insurance for inpatients admitted to all secondary- and tertiary-care hospitals between January 2020 and December 2021 in Korea. 15.9% (58/395) of hospitals were KONAS participants, among which the proportion of hospitals with > 900 beds (31.0% vs.2.6%, P < 0.001) and tertiary care (50.0% vs. 5.2%, P < 0.001) was higher than that among non-participants. The consumption of antibiotics targeting antimicrobial-resistant gram positive bacteria (33.7 vs. 27.1 days of therapy [DOT]/1,000 patient-days, P = 0.019) and antibiotics predominantly used for resistant gram-negative bacteria (4.8 vs. 3.7 DOT/1,000 patient-days, P = 0.034) was higher in KONAS-participating versus -non-participating hospitals. The current KONAS data do not fully represent all secondary- and tertiary-care hospitals in Korea; thus, the KONAS results should be interpreted with caution.
7.Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy.
Min Kyu KANG ; Dongryul OH ; Kwan Ho CHO ; Sung Ho MOON ; Hong Gyun WU ; Dae Seog HEO ; Yong Chan AHN ; Keunchil PARK ; Hyo Jung PARK ; Jun Su PARK ; Ki Chang KEUM ; Jihye CHA ; Jun Won KIM ; Yeon Sil KIM ; Jin Hyoung KANG ; Young Taek OH ; Ji Yoon KIM ; Sung Hwan KIM ; Jin Hee KIM ; Chang Geol LEE
Cancer Research and Treatment 2015;47(4):871-878
PURPOSE: To define the role of neoadjuvant and concurrent chemotherapy in stage II nasopharyngeal carcinoma, we compared the treatment outcomes of patients treated with curative radiotherapy with or without chemotherapy. MATERIALS AND METHODS: From 2004 to 2011, 138 patients with American Joint Committee on Cancer (AJCC) 2002 stage II nasopharyngeal carcinoma were treated with curative radiotherapy in 12 hospitals in South Korea. Treatment methods included radiotherapy alone in 34 patients, neoadjuvant chemotherapy followed by radiotherapy alone in seven, concurrent chemoradiotherapy in 80, and neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in 17. Adjuvant chemotherapy was used in 42 patients. Total radiation dose ranged from 64 Gy to 74.2 Gy (median, 70 Gy). RESULTS: Median follow-up was 48 months (range, 7 to 97 months) for all patients. At the last follow-up, 13 patients had died and 32 had experienced treatment failure; locoregional failure occurred in 14, distant failure in 16, and both in two. Five-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival, and overall survival were 86.2%, 85.5%, 74.4%, and 88.2%, respectively. Multivariate analyses showed that the significant prognostic factors were concurrent chemotherapy and N stage for locoregional relapse-free survival, concurrent chemotherapy for progression-free survival, and age and N stage for overall survival. Neither neoadjuvant nor concurrent chemotherapy improved distant metastasis-free survival. CONCLUSION: Concurrent chemotherapy significantly improved 5-year locoregional relapse-free survival and progression-free survival in stage II nasopharyngeal carcinoma. However, neoadjuvant chemotherapy failed to improve either.
Chemoradiotherapy
;
Chemotherapy, Adjuvant
;
Disease-Free Survival
;
Drug Therapy*
;
Follow-Up Studies
;
Humans
;
Joints
;
Korea
;
Multivariate Analysis
;
Radiotherapy*
;
Treatment Failure
8.ERRATUM: Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy.
Min Kyu KANG ; Dongryul OH ; Kwan Ho CHO ; Sung Ho MOON ; Hong Gyun WU ; Dae Seog HEO ; Yong Chan AHN ; Keunchil PARK ; Hyo Jung PARK ; Jun Su PARK ; Ki Chang KEUM ; Jihye CHA ; Jun Won KIM ; Yeon Sil KIM ; Jin Hyoung KANG ; Young Taek OH ; Ji Yoon KIM ; Sung Hwan KIM ; Jin Hee KIM ; Chang Geol LEE
Cancer Research and Treatment 2016;48(1):425-425
In this article, an protocol number error was found in the last paragraph of the introduction part, page 872.